Navigation Links
Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:10/15/2010

CARLSBAD, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 11:00 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
2. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
4. Prolong Pharmaceuticals Secures $30 Million in Funding
5. Amylin Pharmaceuticals to Webcast Third Quarter Results
6. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
7. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
10. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
11. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... PARK, Ill., Oct. 20 Abbott has,received a ... Drug,Administration (FDA) for its New Drug Application (NDA) ... is,evaluating the FDA Complete Response Letter, will discuss ... update when appropriate., Abbott is seeking the ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader in ... scientific,posters featuring both patient cases and laboratory research ... presented this week at the American,Society of Anesthesiologists ... Dr. Arie Blitz, Director of Heart Transplantation and ...
Cached Medicine Technology:Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3
(Date:8/28/2014)... greater amounts of yellow pigment in your eyes could ... conditions, a new study reports. In a laboratory ... order to test the distance vision of people with ... in their eyes. The volunteers had widely varying ... nutrients lutein and zeaxanthin, according to the researchers, led ...
(Date:8/28/2014)... GreenRushReview.com, a website dedicated to ... “Video” section located at http://www.greenrushreview.com/category/videos/ , which ... cannabis companies in video format. In the site’s ... news clips, interviews, and other short videos discussing ... the videos can also be found on the ...
(Date:8/28/2014)... Alexandria, VA (PRWEB) August 28, 2014 ... Foundation) will interview Stephen Isaacs, the chairperson, president and ... the Foundation’s Meet the Mesothelioma Experts live ... Foundation’s executive director and mesothelioma expert nurse practitioner, ... the interview will be Aduro BioTech’s experimental therapy for ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of prediabetes ... help clients and online readers send out summer healthfully ... Ashley developed variations of Roasted Veggie Pizza , ... PreDiabetes Centers Roasted Veggie Pizza recipe is made with ... a cheese substitute–ideal for people who are lactose intolerant ...
(Date:8/28/2014)... 2014 veEDIS Clinical Systems, LLC ... System (EDIS), in Lawrence Medical Center, located in ... to document patient care, veEDIS is a key ... well as the authorized, confidential exchange of patient ... veEDIS technology, designed in accordance with clinical workflows ...
Breaking Medicine News(10 mins):Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... COPD or chronic obstructive pulmonary disease is a ... // and is associated with severe emphysema or ... can reduce the mortality rate and number of ... study conducted by researchers from the University of ...
... say transmission of genital herpes to others is the ... study shows //the drug valacyclovir may significantly reduce the ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ...
... change the way doctors treat certain prostate cancer patients.The ... cancer patient are grade, PSA level and pathologic stage. ... the Gleason grading system or a Gleason score (GS). ... cancer is seven. In a new study, researchers look ...
... A new study shows the drug valacyclovir may significantly ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ... contagious. Participants with herpes were given ...
... since it interferes with eating and drinking. Children are ... the importance of maintaining// their normal fluid intake despite ... tonsillectomy procedure using less energy than the standard electrocautery ... ,During a tonsillectomy using the electrocautery method, a ...
... by researchers say it is a misconception to believe ... housebound people.// ,Researchers examined 150 children and ... vitamin D. Among the participants, all African-American, East African, ... as were all patients younger than 30. Five patients ...
Cached Medicine News:
Antigenic Free Protein S, ELISA Method...
... Assay for the Quantitative ... Protein S level based ... Va Inhibition by STA© ... free of Protein S; ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: